Therapeutic vaccine
GI-19007, a Novel Saccharomyces cerevisiae-Based Therapeutic Vaccine against Tuberculosis
... a therapeutic vaccine can cure the animal, and it may be that the best we can hope for is a candidate that slows the course of the infection, and reduces lung damage to some extent, while a parallel search ...
14
A simple, clinically relevant therapeutic vaccine shows long-term protection in an aggressive, delayed-treatment B lymphoma model
... develop therapeutic vaccine that can enhance tumor antigen–specific ...in therapeutic vaccines have been explored (27, ...in therapeutic cancer vaccine has been found to be promising ...
17
Virus-Like Vesicle-Based Therapeutic Vaccine Vectors for Chronic Hepatitis B Virus Infection
... novel vaccine vector that lacks detect- able pathogenicity in mouse and monkey models (7, ...a vaccine vector while still lacking detectable pathogenicity ...a therapeutic vaccine for chronic ...
9
An autophagosome based therapeutic vaccine for HBV infection: a preclinical evaluation
... candidate therapeutic vaccines for patients with chronic HBV infection is greatly hampered by the lack of clinical relevant mouse ...HBV therapeutic vaccine based on autop- hagosomes derived from HBV ...
11
Novel therapeutic vaccine for Diabetes mellitus: Literature Review
... develop therapeutic vaccines against diabetes ...developing vaccine for insulin-dependent diabetes mellitus. Therapeutic vaccination with hsp60 epitope p277 can arrest the spontaneous diabetogenic ...
11
Targeting nicotine addiction: the possibility of a therapeutic vaccine
... classical vaccine constructs made up of a an adjuvant and a nicotine carrier protein conjugate, and are administered by ...The vaccine developed by Sanderson et al at the University of Nebraska uses a ...
14
Progress in the development of a therapeutic vaccine for breast cancer
... enrolled; all had breast or ovarian cancer, had been heavily pretreated and had measurable disease. Prior to collection of autologous DCs, patients were off systemic treatments and immunosuppressive drugs, including ...
12
Multi-target chimaeric VLP as a therapeutic vaccine in a model of colorectal cancer
... a therapeutic treatment in a murine model of CRC. The multi-target vaccine was at least as efficacious as each mono-target vaccine, with trends suggesting an improvement in both delaying tumour ...
13
An Adjuvanted Herpes Simplex Virus 2 Subunit Vaccine Elicits a T Cell Response in Mice and Is an Effective Therapeutic Vaccine in Guinea Pigs
... ICP4 and gD2 with Matrix M-2 adjuvant was chosen as a ther- apeutic vaccine candidate for the following reasons. (i) ICP4, an HSV immediate-early (IE) gene product, was identified by our antigen screening platform ...
13
Patients’ high acceptability of a future therapeutic HIV vaccine in France: a French paradox?
... a therapeutic vaccine became ...the vaccine, notably the duration of its effectiveness: 44% of participants expected it to be effective for ...
10
Cross-Reactivity, Epitope Spreading, and De Novo Immune Stimulation Are Possible Mechanisms of Cross-Protection of Nonvaccine Human Papillomavirus (HPV) Types in Recipients of HPV Therapeutic Vaccines
... HPV therapeutic vaccine (PepCan), which used a Candida skin test reagent (Candin; Nielsen Biosciences, San Diego, CA) as a novel vaccine adjuvant ...in vaccine (modified Vaccinia Ankara with ...
9
Therapeutic Mucosal Vaccination of Herpes Simplex Virus 2-Infected Guinea Pigs with Ribonucleotide Reductase 2 (RR2) Protein Boosts Antiviral Neutralizing Antibodies and Local Tissue-Resident CD4+ and CD8+ TRM Cells Associated with Protection against Recurrent Genital Herpes
... develop therapeutic vaccines than prophylactic vaccines because of the many strategies employed by HSV-1 and HSV-2 to evade control by the host’s immune system, which are in place in already infected individuals ...
24
The therapeutic HIV Env C5/gp41 vaccine candidate Vacc C5 induces specific T cell regulation in a phase I/II clinical study
... In this phase I/II trial the therapeutic vaccine candidate Vacc-C5 was administered over six months with initial immunisation and two booster periods in the presence of ART. The primary objective was to ...
12
Enhancing T-Cell Responses to Vaccination of HIV-1 infected Subjects on Antiretroviral Therapy
... traditional vaccine strategies against HIV-1, the results are troubled with safety ...a vaccine remains elusive. The question also arises whether a vaccine that is effective in a prophylactic setting ...
178
A therapeutic cancer vaccine against GL261 murine glioma
... lotype; and (3) an “antigenic” component which is spe- cific for the tumor (e.g., GL261). It should be possible to extend this immunotherapy approach to human subjects with GBM and test it through properly designed ...
9
Human Papillomavirus Type 16 E5 Protein as a Therapeutic Target
... a therapeutic vaccine to target and eliminate the E5-expressing cells may be a good strategy to prevent premalignant lesions from progressing toward invasive cervical ...and therapeutic vaccines to ...
14
Combination immunotherapy and active specific tumor cell vaccination augments anti cancer immunity in a mouse model of gastric cancer
... To further enhance the induction of tumor-specific T cells, vaccines are generally combined with adjuvants like GM-CSF, KLH or CpG [33-36]. Gene-modified tumor cells that continuously secrete low levels of GM- CSF have ...
14
TLR3 agonist and CD40 targeting vaccination induces immune responses and reduces HIV 1 reservoirs
... hu-mice can initiate T cell immu- nity in response to infection or vac- cination (41–46). Hu-mice support HIV-1 infection and are proven rel- evant and robust models to study HIV-1 persistence, pathogenesis, and therapy ...
11
iNKT/CD1d-antitumor immunotherapy significantly increases the efficacy of therapeutic CpG/peptide-based cancer vaccine
... CpG-ODN vaccine, but most importantly OVA-specific CTL numbers increased two-fold in the tumors upon combined OVA/CpG-ODN vaccine and CD1d-anti-HER2 therapy as compared to vaccine ...the ...
12
Therapeutic Transcutaneous Immunization with a Band-Aid Vaccine Resolves Experimental Otitis Media
... and therapeutic TCI strategies against OM due to NTHI ...administer vaccine formulations noninvasively (ultimately to ...a vaccine formulation on intact unmodified skin, with the goal of facilitating ...
8